Engitix Ltd. has entered a strategic collaboration with GSK to identify and validate new therapeutic targets aimed at reversing liver fibrosis. The partnership leverages Engitix’s human extracellular matrix (ECM) platform and multi-omics data alongside GSK’s drug development expertise. Engitix may receive up to £44.5 million upfront and additional milestone payments, while GSK will lead further research and commercialization of any discovered targets. This collaboration focuses on fibrosis regression mechanisms, potentially transforming treatment options for liver fibrosis patients.
Jefferies reaffirmed its buy rating and 2,500p price target on GSK after a New York healthcare conference discussion with GSK's oncology head. The bank emphasized four near-term catalysts in GSK's oncology pipeline, including new data presentations f...
Jefferies reaffirmed its buy rating on GSK, emphasizing four near-term catalysts in the company's oncology pipeline following insights from a New York healthcare conference. GSK plans to present new data on its B7H3 antibody-drug conjugate, a targete...
Biotech and pharma mergers and acquisitions (M&A) reached $106 billion across 201 deals in early 2026, driven by urgent needs to replace revenue from expiring drug patents and renewed investor interest. Despite rising interest rates and inflation, de...
